IVUS in Femoropopliteal PCI: Should We Start Using It?

For approximately two decades now, PCI has been the treatment of choice in femoropopliteal territory, and even though technological developments and increasing operator experience have indeed improved outcomes, IVUS (which has showed great benefits in PCI, even reducing left main mortality) is hardly used in this territory. 

IVUS en la ATP femoropoplítea: ¿deberíamos comenzar a utilizarlo?

This was a prospective randomized controlled study including 150 patients: 74 angiography guided and 76 IVUS guided

Primary end point was freedom from binary stenosis guided by IVUS at 12 months (stenosis ≥50% or systolic peak velocity ≥2.4). Secondary end point was TLR because of symptoms, periprocedural complications and MAE (amputation within 30 days, death, MI and stroke) within 12 months after index procedure. 

There were no differences between the populations as regards clinical characteristics and risk factors, neither were there differences in angiographic characteristics or strategy (POBA, BARE stents, DES or drug eluting balloons). Diameters and length were also similar, except for the use of drug eluting balloons, which were longer in the IVUS group. 

At 12 month follow up, the primary end point resulted in favor of the IVUS group (72.4% vs 55.4%; P= 0.008). There were no differences in freedom from TLR within 12 months after index procedure (84.2% and 82.4%) or in MAE. 

Read also: Wire Jailing at Side Branch to Prevent Occlusion After Main Vessel Stenting: Should It Be the Standard of Care?

Neither were there differences between populations as regards binary restenosis when compared against POBA, BARE stents or DES, but there were differences when using drug eluting balloons in favor of the IVUS group (9.1% vs. 37.5% P= 0.004).

IVUS showed longer lesions and larger vessel diameter compared against angiography guided PCI (diameter 5.60 mm vs. 5.10 mm P<0.001 and length 140 mm vs. 120 mm P=0.01), in addition to nearly 80% of change in strategy.

Conclusion

The use of IVUS showed significant reduction of restenosis rate after endovascular intervention. This is the first study to show IVUS improves evolution in femoropopliteal interventions. This benefit might be related to the use of drug eluting balloons. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board, SOLACI.org.

Original Title: The Impact of Intravascular Ultrasound on Femoropopliteal Artery Endovascular Interventions A Randomized Controlled Trial.

Reference: Richard B. Allan, et al. J Am Coll Cardiol Intv 2022;15:536–546. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...